Vivani completes dosing in 20-participant NPM-139 trial
Vivani Medical announced successful dosing of all SLIM-1 trial participants, evaluating its NPM-139 implant ahead of schedule. With data expected in 2026, this advance follows a recent partnership with Novo Nordisk.
View filing at SEC.gov →